Eton Pharmaceuticals (ETON) Q3 2024 earnings summary

Executive summary

• Achieved total Q3 2024 revenue of $10.3 million, marking the 15th consecutive quarter of sequential product revenue growth and the first positive GAAP net income from product sales, one quarter ahead of target.

• Product sales grew 40% year-over-year, driven by ALKINDI SPRINKLE and Carglumic Acid, with new launches of Nitisinone and PKU GOLIKE contributing incremental sales.

• Advanced three-pillar strategy: organic portfolio growth, pipeline advancement, and value-creating business development, including the acquisition of Increlex® for $22.5 million plus inventory and milestone payments, expected to close near year-end 2024.

• FDA accepted ET-400 NDA for review with a PDUFA date of February 28, 2025; pivotal study for ET-600 initiated with NDA submission targeted for Q1 2025 if results are positive.

• Gross profit for Q3 2024 was $6.3 million, up from $4.4 million in Q3 2023.

Financial highlights

• Q3 2024 revenue was $10.3 million, up 47% year-over-year; net product sales rose 40% to $9.8 million.

• Net income was $0.6 million ($0.02 per share), compared to a net loss of $0.6 million (loss of $0.02 per share) in Q3 2023.

• Cash and cash equivalents at September 30, 2024 were $20.3 million; generated $2.9 million in operating cash flow during the quarter.

• R&D expenses for Q3 2024 were $0.5 million (down from $0.6 million); G&A expenses increased to $5.3 million (up from $4.3 million) due to higher sales, marketing, and legal costs.

• Gross margin for Q3 2024 was approximately 61%.

Outlook and guidance

• Increlex® acquisition expected to close by year-end 2024 and be accretive to 2025 earnings; ET-400 commercial launch anticipated after FDA approval in early 2025.

• Combined peak sales of ET-400 and ALKINDI SPRINKLE projected to exceed $50 million annually.

• Management expects existing cash and product revenues to fund operations and capital expenditures for at least the next twelve months.

• Plans to reach $100 million in revenue and a $1 billion market cap in the coming years, supported by new product launches and acquisitions.

• Sales force to be realigned and expanded in 2025 to support new product launches and maximize portfolio revenue.